Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: Results of a pilot study

David P. Steensma, Ruben A. Mesa, Chin Yang Li, Leigh Gray, Ayalew Tefferi

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Patients with myelofibrosis with myeloid metaplasia (MMM) often experience debilitating constitutional symptoms such as drenching night sweats, profound fatigue, unexplained fevers, and unintentional weight loss. Tumor necrosis factor (TNF) contributes to organ fibrosis and hypercatabolic symptoms in a variety of disease states. We conducted an open-label pilot study of etanercept, a soluble TNF receptor, administered at a dose of 25 mg subcutaneously twice weekly for up to 24 weeks in 22 patients with MMM. Of 20 evaluable patients, 12 (60%) experienced an improvement in constitutional symptoms, and 4 (20%) had an objective response (improvement in peripheral cytopenias or spleen size). The degree of marrow fibrosis was unchanged, and only minor changes in overall marrow cellularity were observed. Toxicity was mild, with injection site reactions (20%) and minor infections (10%) as the most common side effects. One patient developed reversible pancytopenia. Etanercept may be useful for palliation of constitutional symptoms in MMM.

Original languageEnglish (US)
Pages (from-to)2252-2254
Number of pages3
JournalBlood
Volume99
Issue number6
DOIs
StatePublished - Mar 15 2002

Fingerprint

Primary Myelofibrosis
Tumor Necrosis Factor Receptors
Toxicity
Labels
Fibrosis
Tumor Necrosis Factor-alpha
Bone Marrow
Fatigue of materials
Pancytopenia
Sweat
Fatigue
Weight Loss
Fever
Spleen
Injections
Etanercept
Infection

ASJC Scopus subject areas

  • Hematology

Cite this

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia : Results of a pilot study. / Steensma, David P.; Mesa, Ruben A.; Li, Chin Yang; Gray, Leigh; Tefferi, Ayalew.

In: Blood, Vol. 99, No. 6, 15.03.2002, p. 2252-2254.

Research output: Contribution to journalArticle

@article{bbb11961a14645de954c1749f73b489e,
title = "Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: Results of a pilot study",
abstract = "Patients with myelofibrosis with myeloid metaplasia (MMM) often experience debilitating constitutional symptoms such as drenching night sweats, profound fatigue, unexplained fevers, and unintentional weight loss. Tumor necrosis factor (TNF) contributes to organ fibrosis and hypercatabolic symptoms in a variety of disease states. We conducted an open-label pilot study of etanercept, a soluble TNF receptor, administered at a dose of 25 mg subcutaneously twice weekly for up to 24 weeks in 22 patients with MMM. Of 20 evaluable patients, 12 (60{\%}) experienced an improvement in constitutional symptoms, and 4 (20{\%}) had an objective response (improvement in peripheral cytopenias or spleen size). The degree of marrow fibrosis was unchanged, and only minor changes in overall marrow cellularity were observed. Toxicity was mild, with injection site reactions (20{\%}) and minor infections (10{\%}) as the most common side effects. One patient developed reversible pancytopenia. Etanercept may be useful for palliation of constitutional symptoms in MMM.",
author = "Steensma, {David P.} and Mesa, {Ruben A.} and Li, {Chin Yang} and Leigh Gray and Ayalew Tefferi",
year = "2002",
month = "3",
day = "15",
doi = "10.1182/blood.V99.6.2252",
language = "English (US)",
volume = "99",
pages = "2252--2254",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia

T2 - Results of a pilot study

AU - Steensma, David P.

AU - Mesa, Ruben A.

AU - Li, Chin Yang

AU - Gray, Leigh

AU - Tefferi, Ayalew

PY - 2002/3/15

Y1 - 2002/3/15

N2 - Patients with myelofibrosis with myeloid metaplasia (MMM) often experience debilitating constitutional symptoms such as drenching night sweats, profound fatigue, unexplained fevers, and unintentional weight loss. Tumor necrosis factor (TNF) contributes to organ fibrosis and hypercatabolic symptoms in a variety of disease states. We conducted an open-label pilot study of etanercept, a soluble TNF receptor, administered at a dose of 25 mg subcutaneously twice weekly for up to 24 weeks in 22 patients with MMM. Of 20 evaluable patients, 12 (60%) experienced an improvement in constitutional symptoms, and 4 (20%) had an objective response (improvement in peripheral cytopenias or spleen size). The degree of marrow fibrosis was unchanged, and only minor changes in overall marrow cellularity were observed. Toxicity was mild, with injection site reactions (20%) and minor infections (10%) as the most common side effects. One patient developed reversible pancytopenia. Etanercept may be useful for palliation of constitutional symptoms in MMM.

AB - Patients with myelofibrosis with myeloid metaplasia (MMM) often experience debilitating constitutional symptoms such as drenching night sweats, profound fatigue, unexplained fevers, and unintentional weight loss. Tumor necrosis factor (TNF) contributes to organ fibrosis and hypercatabolic symptoms in a variety of disease states. We conducted an open-label pilot study of etanercept, a soluble TNF receptor, administered at a dose of 25 mg subcutaneously twice weekly for up to 24 weeks in 22 patients with MMM. Of 20 evaluable patients, 12 (60%) experienced an improvement in constitutional symptoms, and 4 (20%) had an objective response (improvement in peripheral cytopenias or spleen size). The degree of marrow fibrosis was unchanged, and only minor changes in overall marrow cellularity were observed. Toxicity was mild, with injection site reactions (20%) and minor infections (10%) as the most common side effects. One patient developed reversible pancytopenia. Etanercept may be useful for palliation of constitutional symptoms in MMM.

UR - http://www.scopus.com/inward/record.url?scp=0037085756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037085756&partnerID=8YFLogxK

U2 - 10.1182/blood.V99.6.2252

DO - 10.1182/blood.V99.6.2252

M3 - Article

C2 - 11877307

AN - SCOPUS:0037085756

VL - 99

SP - 2252

EP - 2254

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -